

Review

Not peer-reviewed version

Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era

[Is aventurato](#)*

Posted Date: 1 November 2023

doi: 10.20944/preprints202311.0017.v1

Keywords: nanomedicine; CNS cancer; therapeutics; blood-brain barrier; personalized medicine; nanoparticles; COVID-19; drug delivery; regulatory landscape; precision oncology



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Review

Current Status of Nanomedicine in CNS Cancer Therapeutics in the Post-COVID-19 Era

Ítalo Aventurato * and Montano Maskara

Department of Neurology, University of Campinas (UNICAMP), Campinas, Brazil

* Correspondence: Dr. Ítalo Aventurato, Department of Neurology, University of Campinas (UNICAMP), Campinas, Brazil. Email: aventuratois@gmail.com

Abstract: Central Nervous System (CNS) cancers pose a formidable challenge in the medical world, characterized by aggressive behaviors and limited therapeutic options. The emergence of nanomedicine has offered new hope in CNS cancer treatment. The COVID-19 pandemic has further accelerated the need for innovative therapeutic strategies, emphasizing the significance of nanomedicine in this era. This mini review explores the current status of nanomedicine in CNS cancer therapy, with a particular focus on the post-COVID-19 landscape. We discuss the unique challenges presented by CNS cancers, the potential of nanomedicine in overcoming these challenges, and the recent developments in the field. Additionally, we highlight the lessons learned from the pandemic and how they can be applied to improve CNS cancer therapeutics. We also shed light on the evolving regulatory landscape and the prospects of personalized nanomedicine in CNS cancer treatment. The integration of nanomedicine in CNS cancer therapy is becoming increasingly promising, and its role in the post-COVID-19 era is poised to shape the future of neuro-oncology.

Keywords: nanomedicine; CNS cancer; therapeutics; blood-brain barrier; personalized medicine; nanoparticles; COVID-19; drug delivery; regulatory landscape; precision oncology

1. Introduction

Central Nervous System (CNS) cancers, including gliomas and medulloblastomas, are notorious for their aggressive behavior and limited treatment options [1]. The blood-brain barrier (BBB) presents a formidable challenge, hindering the delivery of therapeutic agents to the brain. The emergence of nanomedicine, a multidisciplinary field at the intersection of nanotechnology, medicine, and pharmaceuticals, has offered promising solutions to overcome these obstacles [2,3]. In the post-COVID-19 era, the importance of innovative and efficient therapies has been underscored, further emphasizing the role of nanomedicine in CNS cancer treatment [4].

This mini review provides an overview of the current status of nanomedicine in CNS cancer therapeutics and explores the potential implications and challenges in the post-COVID-19 landscape. We will discuss the unique challenges posed by CNS cancers, the innovative strategies offered by nanomedicine, the latest advancements in the field, and the lessons learned from the pandemic that can be applied to CNS cancer therapy.

2. Challenges in CNS Cancer Therapy

CNS cancers present a multitude of challenges that have traditionally hindered effective treatment [5]. These challenges include:

- Blood-Brain Barrier (BBB): The BBB is a highly selective barrier that limits the passage of therapeutic agents into the brain, making drug delivery to CNS tumors particularly challenging. Traditional chemotherapy drugs often struggle to reach their target in sufficient quantities [6].
- Heterogeneity: CNS cancers exhibit significant heterogeneity, both within and between patients. This heterogeneity complicates treatment decisions and necessitates personalized therapeutic approaches [7].

- Invasive Nature: CNS cancers, especially high-grade gliomas, have an invasive nature, infiltrating surrounding brain tissue. This makes complete surgical resection nearly impossible and contributes to high rates of recurrence [8].

- Resistance to Therapy: CNS cancers often develop resistance to conventional treatments, including chemotherapy and radiation therapy. This necessitates the development of novel therapeutic approaches [9].

3. Nanomedicine in CNS Cancer Therapy

Nanomedicine harnesses the unique properties of nanoscale materials and devices to overcome these challenges [10,11]. Several key aspects of nanomedicine in CNS cancer therapy include:

- BBB Permeability: Nanoparticles can be engineered to cross the BBB, enabling the targeted delivery of therapeutic agents to the brain. Various strategies, such as surface modifications and drug encapsulation, enhance drug transport across the BBB [10,12].

- Targeted Therapy: Nanoparticles can be designed to target specific receptors or biomarkers on cancer cells, enabling precision medicine approaches. This minimizes off-target effects and enhances the therapeutic index [11,12].

- Drug Delivery: Nanoparticles can encapsulate therapeutic agents, protecting them from degradation and facilitating controlled release. This results in improved drug bioavailability and reduced toxicity [11,13].

- Imaging and Diagnosis: Nanoparticles can be used as contrast agents for imaging techniques, aiding in the diagnosis and monitoring of CNS tumors. They enable real-time visualization of tumor progression and response to therapy [12,14].

- Combination Therapy: Nanomedicine allows for the co-delivery of multiple therapeutic agents, including chemotherapeutics, targeted drugs, and immunotherapies. This synergistic approach enhances treatment efficacy [10–14].

4. Recent Developments in Nanomedicine for CNS Cancer

Recent advancements in nanomedicine for CNS cancer therapy are highly promising [15]. These developments include:

- Nanoparticle Engineering: Innovations in nanoparticle design have led to enhanced BBB penetration and improved targeting of CNS tumors. Surface modifications and functionalization with ligands have significantly increased the specificity of drug delivery [16].

- Theranostics: The integration of diagnostic and therapeutic functions within nanoparticles has enabled theranostic applications. These nanoparticles can simultaneously deliver therapy while providing real-time imaging of the treatment's effect [17].

- Immunotherapy: Nanomedicine is increasingly being explored in the context of CNS cancer immunotherapy. Nanoparticles can be used to deliver immune checkpoint inhibitors and vaccines to activate the patient's immune system against the tumor [18].

- Nanotechnology-Based Imaging: Nanotechnology-driven advancements in imaging techniques, such as magnetic resonance imaging (MRI) and positron emission tomography (PET), offer enhanced visualization of CNS tumors, aiding in diagnosis and treatment planning [19–21].

- Personalized Medicine: The field of nanomedicine is moving toward personalized treatments, where nanoparticles can be tailored to the individual patient's genetic and molecular profile [22].

5. Lessons from the COVID-19 Pandemic

The COVID-19 pandemic has imparted valuable lessons that can be applied to CNS cancer therapy [23]. These include:

- Telemedicine and Remote Monitoring: The pandemic accelerated the adoption of telemedicine, which can be harnessed for remote monitoring of CNS cancer patients, ensuring timely interventions and reducing the burden of in-person visits [22–24].

- Data Sharing and Collaboration: The importance of global data sharing and collaboration, exemplified by initiatives like COVAX, highlights the need for similar efforts in the field of CNS cancer research [25].

- Flexibility and Adaptability: The pandemic underscored the importance of adaptability and flexibility in healthcare systems. These attributes are crucial for addressing rapidly evolving challenges in CNS cancer therapy [26].

6. Regulatory Landscape

The regulatory landscape for nanomedicine in CNS cancer therapy is evolving. Regulatory agencies, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established guidelines for the development and approval of nanomedicine-based therapeutics [27]. These guidelines emphasize safety, efficacy, and quality control [27–30]. Furthermore, international organizations, such as the World Health Organization (WHO), play a role in ensuring equitable access to nanomedicine-based treatments for CNS cancer on a global scale [29,31–33].

7. The Prospects of Personalized Nanomedicine

As the field of nanomedicine continues to advance, personalized medicine approaches are becoming increasingly feasible [34–38]. By tailoring nanoparticle-based therapies to the unique genetic and molecular characteristics of individual patients, the prospects for improved outcomes in CNS cancer therapy are substantial [39–42].

8. Conclusion

In the post-COVID-19 era, the integration of nanomedicine into CNS cancer therapy offers a promising path forward. Nanoparticles engineered for precise drug delivery, imaging, and diagnostics are revolutionizing the treatment landscape for CNS cancers [1,6,43]. The pandemic has accelerated the adoption of telemedicine, data sharing, and adaptive strategies, all of which can benefit CNS cancer patients. As regulatory guidelines evolve, and personalized nanomedicine becomes more feasible, the future of CNS cancer therapy appears increasingly hopeful. The intersection of nanotechnology and neuro-oncology holds the potential to transform the prognosis and quality of life for patients facing these formidable diseases.

Acknowledgments: The authors would like to acknowledge the support from University of Campinas for providing resources and research facilities for this work.

Conflict of Interest: The authors declare no conflict of interest.

Funding: This research received no external funding.

References

1. Tzeng SY, Green JJ. Therapeutic nanomedicine for brain cancer. *Therapeutic delivery*. 2013 Jun;4(6):687-704.
2. Soni S, Ruhela RK, Medhi B. Nanomedicine in central nervous system (CNS) disorders: a present and future prospective. *Advanced pharmaceutical bulletin*. 2016 Sep;6(3):319.
3. Quader S, Kataoka K, Cabral H. Nanomedicine for brain cancer. *Advanced Drug Delivery Reviews*. 2022 Mar 1;182:114115.
4. Mansoor AK, Thomas S, Sinha JK, Alladi PA, Ravi V, Raju TR. Olfactory tract transection reveals robust tissue-level plasticity by cellular numbers and neurotrophic factor expression in olfactory bulb. *Indian journal of experimental biology*. 2012 Nov;50(11):765-70.
5. Hanif S, Muhammad P, Chesworth R, Rehman FU, Qian RJ, Zheng M, Shi BY. Nanomedicine-based immunotherapy for central nervous system disorders. *Acta Pharmacologica Sinica*. 2020 Jul;41(7):936-53.
6. Ghosh S, Durgvanshi S, Han SS, Bhaskar R, Sinha JK. Therapeutics for the management of cytokine release syndrome in COVID-19. *Current Topics in Medicinal Chemistry*. 2023 Jan 1;23(2):128-42.
7. Yan Lee P, KY Wong K. Nanomedicine: a new frontier in cancer therapeutics. *Current drug delivery*. 2011 May 1;8(3):245-53.
8. Neganova ME, Aleksandrova YR, Sukocheva OA, Klochkov SG. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. In *Seminars in Cancer Biology* 2022 Jun 30. Academic Press.

9. Sachdeva P, Ghosh S, Ghosh S, Han S, Banerjee J, Bhaskar R, Sinha JK. Childhood obesity: a potential key factor in the development of glioblastoma multiforme. *Life*. 2022 Oct 21;12(10):1673.
10. Guo ZH, Khattak S, Rauf MA, Ansari MA, Alomary MN, Razak S, Yang CY, Wu DD, Ji XY. Role of Nanomedicine-Based Therapeutics in the Treatment of CNS Disorders. *Molecules*. 2023 Jan 28;28(3):1283.
11. Kaushik A, Jayant RD, Bhardwaj V, Nair M. Personalized nanomedicine for CNS diseases. *Drug discovery today*. 2018 May 1;23(5):1007-15.
12. Ghosh S, Manchala S, Raghunath M, Sharma G, Singh AK, Sinha JK. Role of phytochemicals in the treatment of obesity: targets, mechanisms and limitations. *Current Topics in Medicinal Chemistry*. 2021 Apr 1;21(10):863-77.
13. Garbayo E, Pascual-Gil S, Rodríguez-Nogales C, Saludas L, Estella-Hermoso de Mendoza A, Blanco-Prieto MJ. Nanomedicine and drug delivery systems in cancer and regenerative medicine. *Wiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology*. 2020 Sep;12(5):e1637.
14. Aftab S, Shah A, Nadhman A, Kurbanoglu S, Ozkan SA, Dionysiou DD, Shukla SS, Aminabhavi TM. Nanomedicine: An effective tool in cancer therapy. *International journal of pharmaceutics*. 2018 Apr 5;540(1-2):132-49.
15. Ghosh S, Sinha JK. Contributions of Medicinal Chemistry During the Pandemic of Covid-19. *Current Topics in Medicinal Chemistry*. 2023 Jan 1;23(2):114.
16. Goncalves AS, Macedo AS, Souto EB. Therapeutic nanosystems for oncology nanomedicine. *Clinical and Translational Oncology*. 2012 Dec;14:883-90.
17. Samarasinghe RM, Kanwar RK, Kanwar JR. The role of nanomedicine in cell based therapeutics in cancer and inflammation. *International Journal of Molecular and Cellular Medicine*. 2012;1(3):133.
18. Ghosh S, Sinha JK, Ghosh S, Sharma H, Bhaskar R, Narayanan KB. A Comprehensive Review of Emerging Trends and Innovative Therapies in Epilepsy Management. *Brain Sciences*. 2023 Sep 11;13(9):1305.
19. Mazur J, Roy K, Kanwar JR. Recent advances in nanomedicine and survivin targeting in brain cancers. *Nanomedicine*. 2018 Jan;13(1):105-37.
20. Markman JL, Rekechenetskiy A, Holler E, Ljubimova JY. Nanomedicine therapeutic approaches to overcome cancer drug resistance. *Advanced drug delivery reviews*. 2013 Nov 30;65(13-14):1866-79.
21. Das P, Avinash PR, Saxena V, Sinha JK. COVID-19: The impact of social isolation on mood, behavior and biological rhythms. *Indian Journal of Mental Health*. 2021;8(1).
22. Reynolds JL, Mahato RI. Nanomedicines for the treatment of CNS diseases. *Journal of Neuroimmune Pharmacology*. 2017 Mar;12:1-5.
23. Carradori D, Gaudin A, Brambilla D, Andrieux K. Application of nanomedicine to the CNS diseases. *International review of neurobiology*. 2016 Jan 1;130:73-113.
24. Sachdeva B, Sachdeva P, Negi A, Ghosh S, Han S, Dewanjee S, Jha SK, Bhaskar R, Sinha JK, Paiva-Santos AC, Jha NK. Chitosan Nanoparticles-Based Cancer Drug Delivery: Application and Challenges. *Marine drugs*. 2023 Mar 28;21(4):211.
25. Saeedi M, Eslamifard M, Khezri K, Dizaj SM. Applications of nanotechnology in drug delivery to the central nervous system. *Biomedicine & pharmacotherapy*. 2019 Mar 1;111:666-75.
26. Rhaman MM, Islam MR, Akash S, Mim M, Nepovimova E, Valis M, Kuca K, Sharma R. Exploring the role of nanomedicines for the therapeutic approach of central nervous system dysfunction: At a glance. *Frontiers in Cell and Developmental Biology*. 2022 Sep 2;10:989471.
27. Ghosh S, Durgvanshi S, Agarwal S, Raghunath M, Sinha JK. Current status of drug targets and emerging therapeutic strategies in the management of Alzheimer's disease. *Current neuropharmacology*. 2020 Sep 1;18(9):883-903.
28. Aparicio-Blanco J, Torres-Suárez AI. Managing CNS Tumors: The Nanomedicine Approach. *New Approaches to the Management of Primary and Secondary CNS Tumors*. 2017 Mar 23:65-94.
29. Wong HL, Wu XY, Bendayan R. Nanotechnological advances for the delivery of CNS therapeutics. *Advanced drug delivery reviews*. 2012 May 15;64(7):686-700.
30. Ghosh S, Sachdeva B, Sachdeva P, Chaudhary V, Rani GM, Sinha JK. Graphene quantum dots as a potential diagnostic and therapeutic tool for the management of Alzheimer's disease. *Carbon Letters*. 2022 Oct;32(6):1381-94.
31. Hatami E, Jaggi M, Chauhan SC, Yallapu MM. Gambogic acid: A shining natural compound to nanomedicine for cancer therapeutics. *Biochimica et Biophysica Acta (BBA)-Reviews on Cancer*. 2020 Aug 1;1874(1):188381.

32. Sriramoju B, K Kanwar R, R Kanwar J. Nanomedicine based nanoparticles for neurological disorders. *Current medicinal chemistry*. 2014 Dec 1;21(36):4154-68.
33. Yu HJ, De Geest BG. Nanomedicine and cancer immunotherapy. *Acta Pharmacologica Sinica*. 2020 Jul;41(7):879-80.
34. Faouzi A, Roullin VG. Think big, start small: How nanomedicine could alleviate the burden of rare CNS diseases. *Pharmaceuticals*. 2021 Jan 30;14(2):109.
35. Mishra P, Mittal AK, Kalonia H, Madan S, Ghosh S, Sinha JK, Rajput SK. SIRT1 promotes neuronal fortification in neurodegenerative diseases through attenuation of pathological hallmarks and enhancement of cellular lifespan. *Current Neuropharmacology*. 2021 Jul 1;19(7):1019-37.
36. Maniam J, Antoniadis CP, Youngson NA, Sinha JK, Morris MJ. Sugar consumption produces effects similar to early life stress exposure on hippocampal markers of neurogenesis and stress response. *Frontiers in molecular neuroscience*. 2016 Jan 19;8:86.
37. von Roemeling C, Jiang W, Chan CK, Weissman IL, Kim BY. Breaking down the barriers to precision cancer nanomedicine. *Trends in biotechnology*. 2017 Feb 1;35(2):159-71.
38. Zhang F, Lin YA, Kannan S, Kannan RM. Targeting specific cells in the brain with nanomedicines for CNS therapies. *Journal of Controlled Release*. 2016 Oct 28;240:212-26.
39. Mostafavi E, Medina-Cruz D, Vernet-Crua A, Chen J, Cholula-Diaz JL, Guisbiers G, Webster TJ. Green nanomedicine: the path to the next generation of nanomaterials for diagnosing brain tumors and therapeutics?. *Expert Opinion on Drug Delivery*. 2021 Jun 3;18(6):715-36.
40. Safdarian M, Trinkka E, Rahimi-Movaghar V, Thomschewski A, Aali A, Abady GG, Abate SM, Abd-Allah F, Abedi A, Adane DE, Afzal S. Global, regional, and national burden of spinal cord injury, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. *The Lancet Neurology*. 2023 Nov 1;22(11):1026-47.
41. Sachdeva B, Sachdeva P, Ghosh S, Ahmad F, Sinha JK. Ketamine as a therapeutic agent in major depressive disorder and posttraumatic stress disorder: Potential medicinal and deleterious effects. *Ibrain*. 2023 Mar;9(1):90-101.
42. Athar M, Das AJ. Therapeutic nanoparticles: State-of-the-art of nanomedicine. *Adv. Mater. Rev*. 2014;1(1):25-37.
43. Ahmed S, Rehman SU, Tabish M. Cancer nanomedicine: a step towards improving the drug delivery and enhanced efficacy of chemotherapeutic drugs. *OpenNano*. 2022 Jun 28:100051.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.